Adjusted EBITDA of USD 26.8m (Arctic: USD 27.4m, Cons.: USD 26.8m)
2020 EBITDA guiding reiterated at USD 80 – 90m, now in low-end of range
Reiterates EBITDA margin target of 30% in 2022 and USD 200m in 2024
Reiterated guiding should be supportive following weak performance
30 Oct 2020
Q3 results in line, reiterates 2020 guiding
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q3 results in line, reiterates 2020 guiding
Aker BioMarine ASA (AKBM:OSL) | 0 0 0.0%
- Published:
30 Oct 2020 -
Author:
Thomas Lorck | Axel Jacobsen -
Pages:
6
Adjusted EBITDA of USD 26.8m (Arctic: USD 27.4m, Cons.: USD 26.8m)
2020 EBITDA guiding reiterated at USD 80 – 90m, now in low-end of range
Reiterates EBITDA margin target of 30% in 2022 and USD 200m in 2024
Reiterated guiding should be supportive following weak performance